Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
DaVita's (DVA) strength in its kidney care segment raises optimism about the stock.
Merit Medical's (MMSI) latest asset acquisition is likely to expand its endoscopy portfolio with a minimally-invasive solution for GERD patients, thereby improving patient outcomes.